KR100443653B1 - 월경 곤란증 치료효과가 있는 건강식품 - Google Patents
월경 곤란증 치료효과가 있는 건강식품 Download PDFInfo
- Publication number
- KR100443653B1 KR100443653B1 KR10-2001-0003140A KR20010003140A KR100443653B1 KR 100443653 B1 KR100443653 B1 KR 100443653B1 KR 20010003140 A KR20010003140 A KR 20010003140A KR 100443653 B1 KR100443653 B1 KR 100443653B1
- Authority
- KR
- South Korea
- Prior art keywords
- dysmenorrhea
- menstrual
- menstruation
- mince
- pain
- Prior art date
Links
- 208000005171 Dysmenorrhea Diseases 0.000 title abstract description 34
- 206010013935 Dysmenorrhoea Diseases 0.000 title abstract description 33
- 235000013305 food Nutrition 0.000 title 1
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 8
- 229920002674 hyaluronan Polymers 0.000 abstract description 8
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- 230000005906 menstruation Effects 0.000 description 24
- 230000002175 menstrual effect Effects 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 206010036618 Premenstrual syndrome Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 230000009247 menarche Effects 0.000 description 7
- 206010006298 Breast pain Diseases 0.000 description 6
- 208000006662 Mastodynia Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010000084 Abdominal pain lower Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 206010006294 Breast oedema Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 231100000548 menstrual delay Toxicity 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 201000000484 premenstrual tension Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
시험항목 | 결과 |
히알루론산(히알루론산나트륨으로서) | 3.18 g/100 g |
시험항목 | 결과 |
열량 | 47 Kcal/100 g |
단백질(계수 6.25) | 4.74 g/100 g |
지질(산분해법) | 2.23 g/100 g |
탄수화물 | 2.10 g/100 g |
나트륨 | 200 mg/100 g |
수분(상압건조법) | 90.29 g/100 g |
회분 | 0.44 g/100 g |
분자량 분포 60∼4,500 | 100% |
수 | % | |
초경이후 | 10 | 22.7 |
초경후 6개월 이내 | 6 | 13.6 |
초경후 2년 이내 | 5 | 11.4 |
초경후 2년 후 | 10 | 22.7 |
출산후 | 8 | 18.2 |
기타 | 5 | 11.4 |
총 | 44 | 100 |
수 | % | |
진통제복용 | 13 | 29.5 |
통증심함 | 25 | 56.8 |
중등정도 | 5 | 11.4 |
미약 | 1 | 23 |
총 | 44 | 100 |
before(n=44) | after(n=44) | |
< 24 days | 1(2.3 %) | 5(11.4 %) |
24-27 days | 4(9.1 %) | 7(15.9 %) |
28-32 days | 28(63.6 %) | 23(52.3 %) |
33-36 days | 7(15.9 %) | 7(15.9 %) |
> 37 days | 4(9.1 %) | 2(4.5 %) |
before(n=44) | after(n=44) | |
< 5 pads | 1(2.3 %) | 2(4.5 %) |
6-10 pads | 7(15.9 %) | 8(18.2 %) |
10-15 pads | 14(31.8 %) | 12(27.3 %) |
15-20 pads | 12(27.3 %) | 14(31.8 %) |
> 20 pads | 10(22.7 %) | 8(18.2 %) |
before(n=44) | after(n=44) | |
thin redish | 0(0 %) | 2(4.5 %) |
redish | 22(50.0 %) | 33(75.0 %) |
purple | 19(43.2 %) | 6(13.6 %) |
dark | 1(2.3 %) | 2(4.5 %) |
etc. | 2(4.5 %) | 1(2.3 %) |
before(n=44) | after(n=44) | |
severe clot | 10(22.7 %) | 4(9.1 %) |
moderate clot | 28(63.6 %) | 19(43.2 %) |
hardly clot | 1(2.3 %) | 15(34.1 %) |
mild clot | 5(11.4 %) | 4(9.1 %) |
ro clot | 0(0 %) | 2(4.5 %) |
before(n=44) | after(n=44) | |
0 symp. | 3(6.8 %) | 7(15.9 %) |
1 symp. | 10(22.7 %) | 15(34.1 %) |
2 symp. | 10(22.7 %) | 15(34.1 %) |
3 symp. | 14(31.8 %) | 6(13.6 %) |
4 symp. | 6(13.6 %) | 1(2.3 %) |
5 symp. | 1(2.3 %) | 0(0 %) |
before(n=44) | after(n=44) | p-value | |||
yes | no | yes | no | ||
우울(Depression) | 16(36.4 %) | 28(63.6 %) | 10(22.7 %) | 34(77.3 %) | ns |
유방통(Mammary pain) | 30(68.2 %) | 14(31.8 %) | 16(36.4 %) | 28(63.6 %) | .003 |
체중(Weight gain) | 8(18.2 %) | 36(81.8 %) | 5(11.4 %) | 39(68.6 %) | ns |
두통(Headache) | 7(15.9 %) | 37(84.1 %) | 9(20.5 %) | 35(79.5 %) | ns |
부종(Edema) | 22(50.0 %) | 22(50.0 %) | 14(31.8 %) | 30(68.2 %) | ns |
기타(Etc.) | 18(40.9 %) | 26(59.1 %) | 13(29.5 %) | 31(70.5 %) | ns |
before(n=44) | after(n=44) | |
1 symp. | 4(9.1 %) | 12(27.3 %) |
2 symp. | 10(22.7 %) | 14(31.8 %) |
3 symp. | 10(22.7 %) | 11(25.0 %) |
4 symp. | 3(6.8 %) | 6(13.6 %) |
5 symp. | 7(15.9 %) | 1(2.3 %) |
6 symp. | 7(15.9 %) | 0(0 %) |
7 symp. | 1(2.3 %) | 0(0 %) |
8 symp. | 2(4.5 %) | 0(0 %) |
before(n=44) | after(n=44) | p-value | |||
yes | no | yes | no | ||
복통(Abdominal pain) | 32(72.7 %) | 12(27.3 %) | 19(43.2 %) | 25(56.8 %) | .005 |
요통(Lower back pain) | 28(63.6 %) | 16(36.4 %) | 23(52.3 %) | 21(47.7 %) | ns |
두통(Headache) | 8(18.2 %) | 36(81.8 %) | 6(13.6 %) | 38(86.4 %) | ns |
피로감(Fatigue) | 24(68.2 %) | 20(31.8 %) | 13(36.4 %) | 31(63.6 %) | .017 |
부종(Edema) | 17(38.6 %) | 27(61.4 %) | 10(22.7 %) | 34(77.3 %) | ns |
소화불량(Dyspepsia) | 16(36.4 %) | 28(63.6 %) | 9(20.5 %) | 35(79.5 %) | ns |
유방통(Mammary pain) | 15(34.1 %) | 29(65.9 %) | 8(18.2 %) | 36(81.8 %) | ns |
대변이상(Abnormal excrements) | 20(45.5 %) | 24(54.5 %) | 9(20.5 %) | 35(79.5 %) | .013 |
기타(Etc.) | 6(13.6 %) | 38(86.4 %) | 5(11.4 %) | 39(88.6 %) | ns |
Mean±S.D. | p-value | |
before treatment - 1st menstration | 19.09±20.61 | <0.001 |
before treatment - 2nd menstration | 27.84±17.17 | <0.001 |
before treatment - 3rd menstration | 36.25±21.81 | <0.001 |
1st menstration - 2nd menstration | 8.75±17.66 | .002 |
1st menstration - 3rd menstration | 17.16±23.78 | <0.001 |
2nd menstration - 3rd menstration | 8.41±15.84 | .001 |
person | % | |
Excellert | 6 | 13.6 |
Very good | 19 | 43.2 |
Good | 13 | 29.5 |
No change | 4 | 9.1 |
bad | 2 | 4.5 |
before(n=44) | after(n=44) | p-value | |||
yes | no | yes | no | ||
복통(Abdominal pain) | 22(50.0 %) | 22(50.0 %) | 12(27.3 %) | 32(72.7 %) | .029 |
before | after | |
1-2 days | 3(6.8 %) | 1(2.3 %) |
2-4 days | 13(31.8 %) | 16(36.4 %) |
4-5 days | 11(25.0 %) | 11(25.0 %) |
5-7 days | 16(36.4 %) | 15(34.1 %) |
7-10 days | 0(0 %) | 1(2.3 %) |
Claims (2)
- A) 냉동된 계관을 해동하고, 0.1%의 염소를 녹인 정제수로 세정하여 잔류혈액을 제거한 다음, 민스를 만들고,B) 민스를 반응기에 넣고 가성소다를 계관고형분에 대해 0.5% 해당량을 가하고 15시간 방치하여 민스를 불린 다음,C) 물에 불은 민스에 프로테아제(protease)를 계관고형분에 대해 0.2% 해당량을 가하여 2.5시간 효소분해시킨 다음, 50 메쉬의 스크린으로 1차 여과하고, 세라이트를 1%가하여 10 미크론의 2차 여과지로 여과한 후,D) 여과한 여액에 활성탄을 가하고 교반한 다음, 탈취, 탈색된 여액을 다시 1 미크론의 여과지로 여과하고 활성탄을 제거하여 제조된 펩티드와 히알루론산을 함유한 계관추출물을 유효성분으로 하는 월경증후군의 조절효과가 있는 건강보조식품.
- 삭제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0003140A KR100443653B1 (ko) | 2001-01-19 | 2001-01-19 | 월경 곤란증 치료효과가 있는 건강식품 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0003140A KR100443653B1 (ko) | 2001-01-19 | 2001-01-19 | 월경 곤란증 치료효과가 있는 건강식품 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0048678A Division KR100447327B1 (ko) | 2003-07-16 | 2003-07-16 | 월경 곤란증 치료효과가 있는 약제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020061970A KR20020061970A (ko) | 2002-07-25 |
KR100443653B1 true KR100443653B1 (ko) | 2004-08-09 |
Family
ID=37488507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0003140A KR100443653B1 (ko) | 2001-01-19 | 2001-01-19 | 월경 곤란증 치료효과가 있는 건강식품 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100443653B1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109224039B (zh) * | 2018-12-11 | 2021-06-22 | 济宁市中医院 | 一种治疗肾脏纤维化的二黄益肾中药组合物 |
-
2001
- 2001-01-19 KR KR10-2001-0003140A patent/KR100443653B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20020061970A (ko) | 2002-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kanauchi et al. | Development of a functional germinated barley foodstuff from brewer's spent grain for the treatment of ulcerative colitis | |
Ettinger | Recurrent nephrolithiasis: Natural history and effect of phosphate therapy: A double-blind controlled study | |
Harris et al. | Treatment of scleromyxedema with melphalan | |
Thrasher et al. | Complications of intravesical chemotherapy | |
Badiali et al. | Effect of wheat bran in treatment of chronic nonorganic constipation: a double-blind controlled trial | |
US5710183A (en) | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent | |
Thanapongsathorn et al. | Clinical trial of oral diosmin (Daflon®) in the treatment of hemorrhoids | |
Johnson et al. | Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine bd with 300 mg ranitidine qds | |
Zouboulis | Adamantiades-Behçet’s disease | |
Friedman et al. | Appraisal of methysergide in treatment of vascular headaches of migraine type | |
KR100479968B1 (ko) | 위장 리파아제 억제제의 용도 | |
Berry et al. | Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis. | |
Corman | Management of postoperative constipation in anorectal surgery | |
US4985257A (en) | Hemorrhoidal treatment and composition | |
KR100443653B1 (ko) | 월경 곤란증 치료효과가 있는 건강식품 | |
US20060263457A1 (en) | Pharmaceutical composition for treatment of emiction disorders caused by benign prostate hyperplasia (BPH) and the method | |
RU2333764C1 (ru) | Средство для лечения и профилактики заболеваний щитовидной железы | |
KR100447327B1 (ko) | 월경 곤란증 치료효과가 있는 약제 | |
CN1750819A (zh) | 治疗或预防病毒感染的方法 | |
JPH05262654A (ja) | 慢性疲労症候群治療剤 | |
Porro et al. | A double‐blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients | |
Scaldaferri et al. | Medical therapy of hemorrhoidal disease | |
RU2182016C2 (ru) | Спазмолитическая композиция, способ получения спазмолитической композиции | |
EP3687314B1 (en) | Composition for the treatment of constipation | |
JPH1129488A (ja) | ピコスルファートナトリウムを含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130729 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140623 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150617 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160616 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170608 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20180614 Year of fee payment: 15 |